Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 4.77

(5.54%)

Net Debt Summary of Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.'s latest annual net debt in 2024 was 161.74 Million USD , up 112.56% from previous year.
Xeris Biopharma Holdings, Inc.'s latest quarterly net debt in 2024 FY was 161.74 Million USD , up 112.56% from previous quarter.
Xeris Biopharma Holdings, Inc. reported annual net debt of 76.09 Million USD in 2023, down 0.0% from previous year.
Xeris Biopharma Holdings, Inc. reported annual net debt of 76.09 Million USD in 2022, up 265.89% from previous year.
Xeris Biopharma Holdings, Inc. reported quarterly net debt of 161.74 Million USD for 2024 Q2, down -11.03% from previous quarter.
Xeris Biopharma Holdings, Inc. reported quarterly net debt of 161.74 Million USD for 2024 FY, up 112.56% from previous quarter.

Annual Net Debt Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual Net Debt of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year	Net Debt	Net Debt Growth
2024	161.74 Million USD	112.56%
2023	76.09 Million USD	0.0%
2022	76.09 Million USD	265.89%
2021	20.79 Million USD	-57.92%
2020	49.42 Million USD	457.46%
2019	-13.82 Million USD	67.12%
2018	-42.04 Million USD	-30.3%
2017	-32.26 Million USD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q3	206 Million USD	27.37%
2024 Q2	161.74 Million USD	-11.03%
2024 FY	161.74 Million USD	112.56%
2024 Q1	181.8 Million USD	1.67%
2024 Q4	212.2 Million USD	3.01%
2023 Q3	147.43 Million USD	-17.55%
2023 Q4	178.81 Million USD	21.29%
2023 FY	76.09 Million USD	0.0%
2023 Q1	54.39 Million USD	27.31%
2023 Q2	178.81 Million USD	228.72%
2022 Q4	42.72 Million USD	24.9%
2022 FY	76.09 Million USD	265.89%
2022 Q3	34.2 Million USD	64.5%
2022 Q2	20.79 Million USD	-26.31%
2022 Q1	28.22 Million USD	18.18%
2021 Q4	23.87 Million USD	15.54%
2021 Q1	81.5 Million USD	1062.53%
2021 Q2	49.42 Million USD	-39.36%
2021 Q3	20.66 Million USD	-58.18%
2021 FY	20.79 Million USD	-57.92%
2020 FY	49.42 Million USD	457.46%
2020 Q3	19.24 Million USD	-50.39%
2020 Q2	38.78 Million USD	1874.85%
2020 Q1	1.96 Million USD	105.73%
2020 Q4	7.01 Million USD	-63.56%
2019 Q1	-44.1 Million USD	62.1%
2019 FY	-13.82 Million USD	67.12%
2019 Q4	-34.26 Million USD	-14.82%
2019 Q3	-29.84 Million USD	-115.85%
2019 Q2	-13.82 Million USD	68.65%
2018 Q2	-42.04 Million USD	0.0%
2018 Q4	-116.36 Million USD	-190.47%
2018 FY	-42.04 Million USD	-30.3%
2018 Q3	-40.05 Million USD	4.72%
2017 Q3	32.26 Million USD	0.0%
2017 FY	-32.26 Million USD	0.0%

Peer Net Debt Comparison of Xeris Biopharma Holdings, Inc.

Name	Net Debt	Net Debt Difference
Arrowhead Pharmaceuticals, Inc.	4.28 Million USD	-3679.019%
Codexis, Inc.	-43.27 Million USD	473.788%
Viridian Therapeutics, Inc.	-81.77 Million USD	297.779%
Organovo Holdings, Inc.	-1.5 Million USD	10832.714%